Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer;Les biomarqueurs émergents du diagnostic, du staging et du pronostic du cancer de la prostate

Progres en Urologie

Volumn 21, Issue 1, 2011, Pages 1-10

  Mazzola, C R E ^a   Ghoneim, T ^a   Shariat, S F ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Biomarker; Metastasis; Prostate cancer; Prostate specific antigen; Radical prostatectomy; Recurrence

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; INTERLEUKIN 6; ISOMERASE; LEUKOCYTE ANTIGEN; PROSTATE CANCER ANTIGEN 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN; TRANSCRIPTION FACTOR ETS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN; TUMOR MARKER;

BLOOD; CANCER STAGING; HUMAN; IMMUNOLOGY; MALE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; SHORT SURVEY;

ANTIGENS, CD; ANTIGENS, NEOPLASM; HUMANS; INTERLEUKIN-6; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; RACEMASES AND EPIMERASES; RECEPTORS, CELL SURFACE; TISSUE KALLIKREINS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 78650525089     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2010.07.004     Document Type: Short Survey

References (30)

1. de La Taille A., Houlgatte A., Houdelette P., Berlizot P., Fournier R., Ricordel I. The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer. Prog Urol 1997, 7(3):455-463.
2. Benchikh El Fegoun A., Villers A. Molecular forms of PSA. Prog Urol 2007, 17(2):165-171.
3. Catalona W.J., Bartsch G., Rittenhouse H.G., Evans C.L., Linton H.J., Amirkhan A., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4ng/ml. J Urol 2003, 170(6 Pt 1):2181-2185.
4. Peyromaure M Pro PSA: a new prostate cancer marker. Prog Urol 2004, 14(4 Suppl):8-11.
5. Stephan C., Kahrs A.M., Cammann H., Lein M., Schrader M., Deger S., et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009, 69(2):198-207.
6. Makarov D.V., Isharwal S., Sokoll L.J., Landis P., Marlow C., Epstein J.I., et al. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009, 15(23):7316-7321.
7. Becker C., Piironen T., Pettersson K., Hugosson J., Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0ng/mL or greater. Urology 2000, 55(5):694-699.
8. Haese A., Graefen M., Steuber T., Becker C., Pettersson K., Piironen T., et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10ng/ml. Prostate 2001, 49(2):101-109.
9. Dhir R., Vietmeier B., Arlotti J., Acquafondata M., Landsittel D., Masterson R., et al. Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004, 171(4):1419-1423.
10. Leman E.S., Cannon G.W., Trock B.J., Sokoll L.J., Chan D.W., Mangold L., et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007, 69(4):714-720.
11. Steuber T., Vickers A., Haese A., Kattan M.W., Eastham J.A., Scardino P.T., et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer 2007, 120(7):1499-1504.
12. Gupta A., Lotan Y., Ashfaq R., Roehrborn C.G., Raj G.V., Aragaki C.C., et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol 2009, 55(5):1124-1133.
13. Svatek R.S., Jeldres C., Karakiewicz P.I., Suardi N., Walz J., Roehrborn C.G., et al. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 2009, 69(8):886-894.
14. Shariat S.F., Kattan M.W., Traxel E., Andrews B., Zhu K., Wheeler T.M., et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004, 10(6):1992-1999.
15. Michalaki V., Syrigos K., Charles P., Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004, 90(12):2312-2316.
16. Wikstrom P., Lissbrant I.F., Stattin P., Egevad L., Bergh A., Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002, 51(4):268-275.
17. Karam J.A., Svatek R.S., Karakiewicz P.I., Gallina A., Roehrborn C.G., Slawin K.M., et al. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res 2008, 14(5):1418-1422.
18. Svatek R.S., Karam J.A., Roehrborn C.G., Karakiewicz P.I., Slawin K.M., Shariat S.F. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res 2008, 14(11):3362-3366.
19. Vlaeminck-Guillem V., Ruffion A., Andre J. Value of urinary PCA3 test for prostate cancer diagnosis. Prog Urol 2008, 18(5):259-265.
20. Groskopf J., Aubin S.M., Deras I.L., Blase A., Bodrug S., Clark C., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006, 52(6):1089-1095.
21. van Gils M.P., Hessels D., van Hooij O., Jannink S.A., Peelen W.P., Hanssen S.L., et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007, 13(3):939-943.
22. Marks L.S., Fradet Y., Deras I.L., Blase A., Mathis J., Aubin S.M., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007, 69(3):532-535.
23. Molinie V., Herve J.M., Lugagne P.M., Yonneau L., Ellard S., Lebret T., et al. [Value of new prostate cancer markers: alpha methylacyl CoA racemase (P504S) and p63]. Prog Urol 2005, 15(4):611-615.
24. Bradley S.V., Oravecz-Wilson K.I., Bougeard G., Mizukami I., Li L., Munaco A.J., et al. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res 2005, 65(10):4126-4133.
25. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005, 353(12):1224-1235.
26. Mosquera J.M., Mehra R., Regan M.M., Perner S., Genega E.M., Bueti G., et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009, 15(14):4706-4711.
27. Attard G., Clark J., Ambroisine L., Fisher G., Kovacs G., Flohr P., et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27(3):253-263.
28. Perner S., Demichelis F., Beroukhim R., Schmidt F.H., Mosquera J.M., Setlur S., et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006, 66(17):8337-8341.
29. Shariat S.F., Canto E.I., Kattan M.W., Slawin K.M. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 2004, 6(2):58-72.
30. Bensalah K., Montorsi F., Shariat S.F. Challenges of cancer biomarker profiling. Eur Urol 2007, 52(6):1601-1609.